• Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of active pharmaceutical ingredients
• The company out-licenses the use of its patented DehydraTECH(TM) technology within the pharmaceutical industry and consumer sectors
• Lexaria has focused on applied R&D to establish areas of investigation for commercial pursuits, with its programs proving successful
• Additionally, Lexaria has a robust intellectual property portfolio with 28 patents granted worldwide as of February 2023

In 2022, Lexaria Bioscience (NASDAQ: LEXX), a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology, achieved several important goals for the year, according to CEO Chris Bunka.

“One of our biggest achievements of 2022 was our greater emphasis on commercial pursuits,” Bunka wrote in his January 2023 letter to shareholders (https://cnw.fm/gm32a). This saw the company acquire new customers, among them Premier Wellness Science Co. Ltd. of Japan, its first client in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.